SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: Online resources and useful tools - a compass in the land of biomarker discovery by Bedognetti, Davide et al.
SITC/iSBTc Cancer Immunotherapy Biomarkers
Resource Document: Online resources and useful
tools - a compass in the land of biomarker discovery
Bedognetti et al.
Bedognetti et al. Journal of Translational Medicine 2011, 9:155
http://www.translational-medicine.com/content/9/1/155 (19 September 2011)REVIEW Open Access
SITC/iSBTc Cancer Immunotherapy Biomarkers
Resource Document: Online resources and useful
tools - a compass in the land of biomarker
discovery
Davide Bedognetti
1,2,3*, James M Balwit
1, Ena Wang
1,2, Mary L Disis
1,4, Cedrik M Britten
5, Lucia G Delogu
1,6,
Sara Tomei
1,2,7, Bernard A Fox
1,8, Thomas F Gajewski
1,9, Francesco M Marincola
1,2 and Lisa H Butterfield
1,10
Abstract
Recent positive clinical results in cancer immunotherapy point to the potential of immune-based strategies to
provide effective treatment of a variety of cancers. In some patients, the responses to cancer immunotherapy are
durable, dramatically extending survival. Extensive research efforts are being made to identify and validate
biomarkers that can help identify subsets of cancer patients that will benefit most from these novel
immunotherapies. In addition to the clear advantage of such predictive biomarkers, immune biomarkers are
playing an important role in the development, clinical evaluation and monitoring of cancer immunotherapies. This
Cancer Immunotherapy Resource Document, prepared by the Society for Immunotherapy of Cancer (SITC, formerly
the International Society for Biological Therapy of Cancer, iSBTc), provides key references and online resources
relevant to the discovery, evaluation and clinical application of immune biomarkers. These key resources were
identified by experts in the field who are actively pursuing research in biomarker identification and validation. This
organized collection of the most useful references, online resources and tools serves as a compass to guide
discovery of biomarkers essential to advancing novel cancer immunotherapies.
Introduction
Immunotherapy has emerged as an important treatment
strategy for patients with cancer. With several recent
approvals by the U.S. Food and Drug Administration
(FDA), cancer immunotherapy has become the latest
addition to the toolbox of effective cancer treatments
that includes chemotherapy, signal transduction inhibi-
tors, anti-angiogenic agents, radiotherapy, and surgery.
Successful development and testing, regulatory
approval and clinical application of cancer immu-
notherapies require the identification and validation of
biomarkers of efficacy. The importance of reliable bio-
markers to guide immune-based and personalized can-
cer therapies is clear. Biomarkers can aid in early
disease diagnosis, help clinicians identify patients most
likely to benefit from these expensive treatments, and
facilitate drug discovery, development and biological/
clinical evaluation of cancer immunotherapies.
For over twenty-five years the Society for Immunother-
apy of Cancer (SITC; formerly the International Society
for Biological Therapy of Cancer, iSBTc) has advanced the
science, development and application of biological ther-
apy/immunotherapy of cancer. The society has long recog-
nized the importance of biomarkers for cancer
immunotherapy, which has been the focus of a number of
SITC/iSBTc symposia and workshops [1-5], and has pub-
lished recommendations [6] and summaries [7-10].
To support the efforts of investigators involved in
research to identify and validate biomarkers for cancer
immunotherapy, the authors and members of the SITC
Biomarkers Taskforce have identified key biomarker refer-
ences and online resources and organized these into this
SITC/iSBTc Cancer Immunotherapy Biomarkers Resource
Document. This document provides an overview of sug-
gested publications and resources for studies on
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document is divided into two sections: Part I: Immu-
notherapy Biomarker References; and Part II: High
Throughput and New Technologies for Biomarker Discov-
ery: Arrays, Platforms, Tools for The Bench and Online
Resources. While many important references and
resources in the field are included in this document, it
does not intend to represent an exhaustive list of all rele-
vant publications, products or resources in the growing,
and important field of immune biomarkers. A comprehen-
sive list of online tools for bioinformatics and molecular
biology research is available from the Bioinformatics Links
Directory [11,12].
A draft of the present document was originally pro-
vided to attendees of the SITC/iSBTc Symposium on
Immuno-Oncology Biomarkers, 2010 and Beyond: Per-
spectives from the iSBTc Biomarker Task Force [1],
which was held September 30, 2010 at the National Insti-
tutes of Health in conjunction with the society’s 25th
Annual Meeting. Following the symposium, the draft
document was posted on the society’s website for open
comment. The comments were reviewed by the authors
and incorporated into this manuscript. The references
and online resources are organized as outlined in Table 1.
Part I. Immunotherapy Biomarker References
1. Guideline and Meeting Reports
Recommendations from the iSBTc/FDA/NCI Workshop on
Immunotherapy Biomarkers
Butterfield LH, Disis ML, Fox BA, et al.: A systematic
approach to biomarker discovery; Preamble to “The
iSBTc-FDA Taskforce on Immunotherapy Biomarkers”.
J Transl Med 6:81, 2008
Butterfield LH, Palucka AK, Britten CM et al:: Recom-
mendations from the iSBTc-SITC/FDA/NCI Workshop
on Immunotherapy Biomarkers, Clin Cancer Res
17:3064-3076, 2010
2009 Report of the US - Japan Workshop on Immunological
Biomarkers in Oncology
Tahara H, Sato M, Thurin M, et al.: Emerging concepts
in biomarker discovery; The US-Japan workshop on
immunological molecular markers in oncology. J Transl
Med 7:45, 2009
2010 Guidelines of the NCI-Investigational Drug Steering
Committee (IDSC) Biomarker Task Force
Dancey JE, Dobbin KK, Groshen S, et al.: Guidelines for
the development and incorporation of biomarker studies
in early clinical trials of novel agents. Clin Cancer Res
16:1745-1755, 2010
2010 Report of the Translational Research Cancer Centers
Consortium (TrC3) Immunotherapy Network Annual
Meeting
Lesinski GB, Carson WE, Repasky EA, et al.: Meeting
Report: The 13th Annual Meeting of the Translational
Research Cancer Centers Consortium (TrC3); Immune
Suppression and the Tumor Microenvironment, Colum-
bus, Ohio; March 1-2, 2010. J Immunother, 2010
2008 Report on EU-USA Workshop on System Biology in
Cancer Research
A e b e r s o l dR ,A u f f r a yC ,B a n e yE ,e ta l . :R e p o r to nE U -
USA workshop: how systems biology can advance can-
cer research (27 October 2008). Mol Oncol 3:9-17, 2009
2007 AACR-FDA-NCI Cancer Biomarkers Collaborative
Consensus Report
Khleif SN, Doroshow JH, Hait WN: AACR-FDA-NCI
Cancer Biomarkers Collaborative Consensus Report:
Advancing the Use of Biomarkers in Cancer Drug
Development. Clin Cancer Res 16:3299-3318, 2010
2005 Report on Workshop on Cancer Biometrics Held at
NIH Masur Auditorium
(This manuscript also includes a brief description of
high throughput technologies)
Lotze MT, Wang E, Marincola FM, et al.: Workshop
on cancer biometrics: identifying biomarkers and surro-
gates of cancer in patients: a meeting held at the Masur
Auditorium, National Institutes of Health. J Immunother
28:79-119, 2005
2002 Report on Workshop on Immunologic Monitoring of
Cancer Vaccine Trials
Keilholz U, Weber J, Finke JH, et al.: Immunologic mon-
itoring of cancer vaccine therapy: results of a workshop
sponsored by the Society for Biological Therapy. J
Immunother 25:97-138, 2002
2. Clinical Trials
A. Recent Immunotherapy Trials in Cancer Patients -
Positive Randomized Phase III Studies
Examples
gp100:209-217 (210M) Peptide Followed by High-
Dose IL-2 - Metastatic Melanoma Schwartzentruber
DJ, Lawson D, Richards J, et al: gp100 peptide vaccine
and interleukin-2 in patients with advanced melanoma.
N Eng J Med 364:2119-27, 2011
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and
Isotretinoin - High-Risk Neuroblastoma Yu AL, Gil-
man AL, Ozkaynak MF, eta al.: Anti-GD2 antibody with
GM-CSF, interleukin-2, and isotretinoin for neuroblas-
toma. N Engl J Med. 363:1324-34, 2010
Ipilimumab and Dacarbazine in Metastaic Mela-
noma Patients - Untreated Metastatic Melanoma
Robert C, Thomas L, Bondarenko I, et al.: Ipilimumab
plus dacarbazine for previously untreated metastatic
melanoma. N Engl J Med 364:2517-26, 2011
Ipilimumab in Metastatic Melanoma Patients - Pre-
viously Treated Metastatic Melanoma Hodi FS, O’Day
SJ, McDermott DF, et al.: Improved survival with ipili-
mumab in patients with metastatic melanoma. N Engl J
Med 363: 711-23, 2010
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Page 2 of 20Sipuleucel-T Immunotherapy - Metastatic Prostate
Cancer Kantoff PW, Higano CS, Shore ND, et al.: Sipu-
leucel-T immunotherapy for castration-resistant prostate
cancer. N Engl J Med 363:411-422, 2010
Interferon a Adjuvant Treatment - High Risk Mela-
noma Eggermont AMM, Suciu S, Santinami M, et al.:
Adjuvant therapy with pegylated interferon alfa-2b ver-
sus observation alone in resected stage III melanoma:
Table 1 Structure of the Biomarker References and Online Resources Provided
Part I. Immunotherapy Biomarker References
1. Guideline and Meeting Reports
2. Clinical Trials
A. Recent Immunotherapy Trials in Cancer Patients - Positive Randomized Phase III Studies
B. Emerging Biomarkers for Immunotherapy of Cancer - Clinical Trials
C. Correlation between Immune Response and Clinical Outcome in Cancer Patients; Positive Studies
3. Gene Expression Profiling in Cancer Immunotherapy
4. Useful Reviews
5. Bioinformatics for Biomarkers Discovery
6. New Technologies for Biomarkers Discovery
7. Standardization and Harmonization of Sample Collection and Use of Immunological Assays
A. Processing, Storage and Shipping of Blood Samples and Serum for Immunological Studies - Technical Considerations
B. Cellular Immunotherapy: Characterization of Cellular Products
C. Assay Standardization and Harmonization
D. Assays for Determination of Antitumor Immune-Response in Clinical Trials
8. Reporting Biomarkers Data in Publications
Part II. High Throughput and New Technologies for Biomarker Discovery: Arrays, Platforms, Tools for The Bench and Online Resources
1. Genomic Biomarkers Discovery
A. Single Nucleotide Polymorphisms (SNPs) Arrays
B. Comparative Genomic Hybridization (CGH) Arrays
C. Mitochondrial Genome Arrays
2. Epigenomic Biomarkers Discovery
A. Methylation Arrays
B. microRNA (miRNA) Arrays
C. Chromatin Immunoprecipitation (ChIP) Arrays (ChIP on chip)
3. Transcriptomic Biomarkers Discovery
A. Expression Arrays
B. Quantitative Assays
4. Proteomic Biomarkers Discovery
A. Protein and Phosphoprotein Assays
B. Multicolor Cytometric Systems
5. Next Generation Sequencing: Whole Genomic and Transcriptomic Sequencing Systems
6. Software and Tools for Data Analysis
A. Microarrays/Sequencing Data Analysis
B. Next Generation Sequencing Data Analysis
C. Multicolor Cytometric Data Analysis
7. Software and Tools for Function and Pathway Analysis
8. siRNA Libraries
9. Public Databases
10. Tools for the Bench and Other Useful Websites
A. Primer Design Software
B. Transcription Factors Binding Sites Prediction Software
C. Design of Antisense Oligonucleotides, Nucleic Acid Probes, siRNA Software
D. miRNA Prediction
E. Alternative Splicing Analysis
F. Linkage Disequilibrium Analysis
G. Analysis Support, Laboratory Optimization and Other Useful Websites
H. Nanotechnology
I. Clinical Trials Registries
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trial. Lancet 372:117-126, 2008
Idiotype Vaccine Therapy - Complete Remission Fol-
licular Lymphoma Schuster SJ, Neelapu SS, Gause BL,
et al: Vaccination with patient-specific tumor-derived
antigen in first remission improves disease-free survival
in follicular lymphoma. J Clin Oncol 20: 2787-2794, 2011
B. Emerging Biomarkers for Immunotherapy of Cancer -
Clinical Trials
Examples
Parameter: HLA Cw*06 Allele
Setting: Interferon a Adjuvant Treatment - High-Risk
Melanoma Gogas H, Kirkwood JM, Falk CS, et al.: Cor-
relation of molecular human leukocyte antigen typing
and outcome in high-risk melanoma patients receiving
adjuvant interferon. Cancer 116:4326-33, 2010
Parameter: CCR5 and CXCR3 Polymorphisms and
Gene Expression
Setting: Adoptive Therapy - Metastatic Melanoma
Bedognetti D, Uccellini L, Wang, et al.: Evaluation of
CXCR3 and CCR5 polymorphisms and gene-expression
as predictive biomarkers of clinical response to adoptive
therapy in melanoma patients. J Immunother 33:860,
2010 (Meeting Abstract)
Parameter: Differentiated Effector Phenotype, ‘’Ba n d
T Lymphocyte Attenuator’’ (BTLA) Expression in CD8
+ TIL
Setting: Adoptive Therapy - Metastatic Melanoma
Laszlo G. Radvanyi, Chantale Bernatchez, Minying
Zhang, et al. Adoptive T cell therapy for metastatic mel-
anoma: The MD Anderson experience. J Immunother
33:863, 2010 (Meeting Abstract)
Parameter: VEGF Serum Level
Setting: IL-2 Therapy - Metastatic Melanoma Saba-
tino M, Kim-Schulze S, Panelli MC, et al.: Serum vascu-
lar endothelial growth factor and fibronectin predict
clinical response to high-dose interleukin-2 therapy. J
Clin Oncol 27:2645-2652, 2009
Parameter: Treg Numbers
Setting: hTERT Pulsed DCs Therapy - Metastatic
Solid Tumors A l o y s i u sM M ,M cK e c h n i eA J ,R o b i n s
RA, et al.: Generation in vivo of peptide-specific cyto-
toxic T cells and presence of regulatory T cells during
vaccination with hTERT (class I and II) peptide-pulsed
DCs. J Transl Med 7, 2009
Parameter: CD54 Expression by APC
Setting: Sipuleucel-T Cellular Immunotherapy -
Metastatic Prostate Cancer Higano CS, Schellhammer
PF, Small EJ, et al.: Integrated data from 2 randomized,
double-blind, placebo-controlled, phase 3 trials of active
cellular immunotherapy with sipuleucel-T in advanced
prostate cancer. Cancer 115:3670-3679, 2009
Parameter: Delta32 CCR5 Polymorphism
Setting: Immunotherapy (IL2/IFNa ±C h e m o t h e r a p y /
Vaccination) - Metastatic Melanoma Ugurel S,
S c h r a m aD ,K e l l e rG ,e ta l . :I m p a c to ft h eC C R 5g e n e
polymorphism on the survival of metastatic melanoma
patients receiving immunotherapy. Cancer Immunol
Immunother 57:685-691, 2008
Parameter: Telomere Length
Setting: Adoptive Therapy - Metastatic Melanoma
Dudley ME, Yang JC, Sherry R, et al.: Adoptive cell ther-
apy for patients with metastatic melanoma: evaluation of
intensive myeloablative chemoradiation preparative regi-
mens. J Clin Oncol 26:5233-5239, 2008
Parameter: CTLA-4 Polymorphisms
Setting: Anti-CTLA-4 Therapy - Metastatic Mela-
noma Breunis WB, Tarazona-Santos E, Chen R, et al.:
Influence of cytotoxic T lymphocyte-associated antigen
4 (CTLA4) common polymorphisms on outcome in
treatment of melanoma patients with CTLA-4 blockade.
J Immunother 31:586-9, 2008
Parameter: CCL5, CCL11, IFN-g, ICOS, CD20
Setting: MAGEA3-Based Vaccination - Metastatic
Melanoma L o u a h e dJ ,G r u s e l l eO ,G a u l i sS ,e ta l . :
Expression of defined genes identified by pretreatment
tumor profiling: Association with clinical responses to
the GSK MAGE- A3 immunotherapeutic in metastatic
melanoma patients (EORTC 16032-18031). J Clin Oncol
26:9045, 2008 (Meeting Abstract)
Parameter: Fc Gamma Receptor Polymorphisms
Setting: Immuno (Trastuzumab) Chemotherapy -
Metastatic Breast Cancer Musolino A, Naldi N, Bortesi
B, et al.: Immunoglobulin G fragment C receptor poly-
morphisms and clinical efficacy of trastuzumab-based
therapy in patients with HER-2/neu-positive metastatic
breast cancer. J Clin Oncol 26:1789-1796, 2008
Parameter: Phosphorylated - STAT-1/STAT-3 Ratio
Setting: Neoadjuvant IFN-a Therapy - Stage IIIB
Melanoma Wang WJ, Edington HD, Rao UNM, et al.:
Modulation of signal transducers and activators of tran-
scription 1 and 3 signaling in melanoma by high-dose
IFN alpha 2b. Clin Cancer Res 13:1523-1531, 2007
Parameter: IL 1b, IL-1a, IL-6, TNF-a, CCL3, CCL4
Setting: Adjuvant IFN-a Therapy - High Risk Mela-
noma Yurkovetsky ZR, Kirkwood JM, Edington HD, et
al Multiplex analysis of serum cytokines in melanoma
patients treated with interferon-alpha 2b. Clin Cancer
Res 13:2422-2428, 2007
Parameter: Autoantibodies and Clinical Manifesta-
tions of Autoimmunity
Setting: Adjuvant IFN-a Therapy - Melanoma Gogas
H, Ioannovich J, Dafni U, et al.: Prognostic significance
of autoimmunity during treatment of melanoma with
interferon. N Engl J Med: 354:709-18, 2006
Parameter: IFN-g Polymorphism
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Page 4 of 20Setting: Immuno (IL-2) Chemotherapy - Metastatic
Melanoma Liu DX, O’Day SJ, Yang DY, et al.: Impact
of gene polymorphisms on clinical outcome for stage IV
melanoma patients treated with biochemotherapy: An
exploratory study. Clin Cancer Res 11:1237-1246, 2005
Parameter: IL-6, PPARG
Setting: BCG - Bladder Cancer Leibovici D, Grossman
HB, Dinney CP, et al.: Polymorphisms in inflammation
genes and bladder cancer: From initiation to recurrence,
progression, and survival. J Clin Oncol 23:5746-5756,
2005
C. Correlation between Immune Response and Clinical
Outcome in Cancer Patients; Positive Studies
Examples
Parameter: Melan-A-tetramer+ Immunity
Setting: High Dose Poly-Epitope Vaccine - Metastatic
Melanoma Dangoor A, Lorigan P, Keilholz U, et al.:
Clinical and immunological responses in metastatic mel-
anoma patients vaccinated with a high-dose poly-epitope
vaccine. Cancer Immunol Immunother 59:863-73, 2010
Parameter: High Interferon-gamma-associated Prolif-
erative CD4+ T-cell Response and Broad Response of
CD8+ Interferon-gamma T Cells
Setting: HPV-16 Vaccine Therapy - Vulvar Intrae-
pithelial Neoplasia Welters MJ, Kenter GG, de Vos
van Steenwijk PJ, et al.: Success or failure of vaccination
for HPV16-positive vulvar lesions correlates with
kinetics and phenotype of induced T-cell responses.
Proc Natl Acad Sci U S A. 107:11895-9, 2010
Parameter: High Interferon-gamma-associated Prolif-
erative CD4+ T-cell Response and Broad Response of
CD8+ Interferon-gamma T Cells
Setting: HPV-16 Vaccine Therap - Vulvar Intrae-
pithelial Neoplasia Kenter GG, Welters MJ, Valentijn
AR, et al.: Vaccination against HPV-16 oncoproteins for
vulvar intraepithelial neoplasia. N Engl J Med 361:1838-
47, 2009
Parameter: Tumor Specific Immune Response
(ELISPOT)
Setting: Tumor Multi-Epitope Vaccine - Metastatic
Melanoma Kirkwood JM, Lee S, Moschos SJ, et al.:
Immunogenicity and antitumor effects of vaccination
with peptide vaccine+/-granulocyte-monocyte colony-sti-
mulating factor and/or IFN-alpha2b in advanced meta-
static melanoma: Eastern Cooperative Oncology Group
Phase II Trial E1696. Clin Canc Res 15:1443-1451, 2009
Parameter: NY-ESO-1-specific B and T Cell Responses
Setting: Anti CTLA-4 Immunotherapy - Metastatic
Melanoma Yuan J, Gnjatic S, Li H, Powel S, et al.:
CTLA-4 blockade enhances polyfunctional NY-ESO-1
specific T cell responses in metastatic melanoma
patients with clinical benefit. Proc Natl Acad Sci U S A.
105:20410-5, 2008
Parameter: Epitope Spreading
Setting: Adenovirus MART-1 Dendritic Cell Vaccina-
tion - Metastatic Melanoma Butterfield LH, Comin-
Anduix B, Vujanovic L, et al.: Adenovirus MART-1-
engineered autologous dendritic cell vaccine for meta-
static melanoma. J immunother 31:294-309, 2008
Parameter: Epitope Spreading
Setting: Dendritic Cell Based Vaccination - Stage II-
IV Melanoma Ribas A, Glaspy JA, Lee Y, et al.: Role of
dendritic cell phenotype, determinant spreading, and
negative costimulatory blockade in dendritic cell-based
melanoma immunotherapy. J Immunother 27:354-367,
2004
Parameter: Epitope Spreading
Setting: Dendritic Cell Based Vaccination - Stage III-
IV Melanoma Butterfield LH, Ribas A, Dissette VB, et
al. Determinant spreading associated with clinical
response in dendritic cell-based immunotherapy for
malignant melanoma. Clin Canc Res 9:998-1008, 2003
Parameter: Epitope Spreading
Setting: Peptide-Pulsed Dendritic Cells Vaccination -
Metastatic Renal Cell Carcinoma Wierecky J, Müller
M R ,W i r t h sS ,e ta l . :I m m u n o l o g i ca n dc l i n i c a l
responses after vaccinations with peptide-pulsed dendri-
tic cells in metastatic renal cancer patients. Cancer Res
66:5910-8, 2006
Parameter: Epitope Spreading
Setting: Her2 Specific Vaccination - Stage III-IV
Breast Cancer Salazar LG, Goodell V, O’Meara M, et
al: Persistent immunity and survival after immunization
with a HER2/neu (HER2) vaccine. J Clin Oncol 27
(15S):2010 (Meeting Abstract)
Parameter: Overall Immunity to MelAgs
Setting: Dendritic Cell Based Vaccination - Meta-
static Melanoma Banchereau J, Palucka AK, Dhodapkar
M, et al. Immune and clinical responses in patients with
metastatic melanoma to CD34(+) progenitor-derived
dendritic cell vaccine. Cancer Res 6451-8. 2001
Parameter: T-cell Response (ELISPOT)
Setting: 12-Peptide Vaccine - Stage IIB-IV - Mela-
noma Slingluff CL, Jr., Petroni GR, Chianese-Bullock
KA, et al.: Immunologic and clinical outcomes of a ran-
domized phase II trial of two multipeptide vaccines for
melanoma in the adjuvant setting. Clin Canc Res
13:6386-6395, 2007
Parameter: Tumor specific IFN-g ELISPOT Response
Setting: Adjuvant Autologous Tumor Lysate Vaccine -
Colon Cancer Barth RJ Jr, Fisher DA, Wallace PK, et
al.: A randomized trial of ex vivo CD40L activation of a
dendritic cell vaccine in colorectal cancer patients:
tumor-specific immune responses are associated with
improved survival. Clin Cancer Res 16:5548-56, 2010
Parameter: Delayed Type IV Hypersensitivity
Setting: Dendritic Cell Vaccine - Stage III-IV Mela-
noma Patients López MN, Pereda C, Segal G, et al:
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noma patients correlates with tumor-specific delayed
type IV hypersensitivity response and reduction of
tumor growth factor beta-expressing T cells. J Clin
Oncol 27:945-52, 2009
Parameter: Delayed Type IV Hypersensitivity
Setting: Adjuvant Autologous Tumor Cell Vaccination
- Stage III-IV Melanoma Patients Baars A, Claessen
AM, van den Eertwegh AJ et al.: Skin tests predict survi-
val after autologous tumor cell vaccination in metastatic
melanoma: experience in 81 patients. Ann Oncol
11:965-70, 2000
Parameter: Delayed Type IV Hypersensitivity
Setting: Allogeneic GM-CSF - Stage I-III Pancreatic
Cancer Jaffee EM, Hruban RH, Biedrzycki B, et al.:
Novel allogeneic granulocyte-macrophage colony-stimu-
lating factor-secreting tumor vaccine for pancreatic can-
cer: a phase I trial of safety and immune activation. J
Clin Oncol 19: 45-56, 2009
Parameter: Delayed Type IV Hypersensitivity
Setting: Dendritic Cell Vaccination - Stage IV Mela-
noma de Vries IJ, Bernsen MR, Lesterhuis WJ, et al:
Immunomonitoring tumor-specific T cells in delayed-
type hypersensitivity skin biopsies after dendritic cell
vaccination correlates with clinical outcome. J Clin
Oncol 23:5779-87, 2005
3. Gene Expression Profiling in Cancer Immunotherapy
Examples
Gajewski TF, Fuertes M, Spaapen R et al.: Molecular
profiling to identify relevant immune resistance mechan-
isms in the tumor microenvironment. Curr Opin Immu-
nol 23:286-92, 2011
Bedognetti D, Wang E, Sertoli MR, Marincola FM:
Gene-expression profiling in vaccine therapy and immu-
notherapy for cancer. Expert Rev Vaccines 6:555-65,
2010
Worschech A, Chen NH, Yu YA, et al.: Systemic treat-
ment of xenografts with vaccinia virus GLV-1h68 reveals
the immunologic facet of oncolytic therapy. BMC Geno-
mics 10, 2009
Harlin H, Meng Y, Peterson AC, et al.: Chemokine
expression in melanoma metastases associated with CD8
(+) T-cell recruitment. Cancer Res 69:3077-3085, 2009
Wang E, Miller LD, Ohnmacht GA, et al.: Prospective
molecular profiling of melanoma metastases suggests
classifiers of immune responsiveness. Cancer Res
62:3581-3586, 2002
Panelli MC, Stashower ME, Slade HB, et al.: Sequential
gene profiling of basal cell carcinomas treated with imi-
quimod in a placebo-controlled study defines the require-
ments for tissue rejection. Genome Biol 8:R8, 2007
Sullivan RJ, Hoshida Y, Brunet J, et al.: A single center
experience with high-dose (HD) IL-2 treatment for
patients with advanced melanoma and pilot investigation
of a novel gene expression signature as a predictor of
response. J Clin Oncol 27:9003, 2009 (Meeting Abstract)
G a j e w s k iT F ,Z h aY ,T h u r n e rB ,e ta l . :A s s o c i a t i o no f
gene expression profile in metastatic melanoma and sur-
vival to a dendritic cell-based vaccine. J Clin Oncol
27:9002, 2009 (Meeting Abstract)
Louahed J, Gruselle O, Gaulis S, et al.: Expression of
defined genes identified by pretreatment tumor profil-
ing: Association with clinical responses to the GSK
MAGE- A3 immunotherapeutic in metastatic melanoma
patients (EORTC 16032-18031). J Clin Oncol 26:9045,
2008 (Meeting Abstract)
Vansteenkiste JF, Zielinski, M, Dahabreh IJ, et al.:
Association of gene expression signature and clinical
efficacy of MAGE-A3 antigen-specific cancer immu-
notherapeutic (ASCI) as adjuvant therapy in resected
stage IB/II non-small cell lung cancer (NSCLC). J Clin
Oncol 26:7501, 2008 (Meeting Abstract)
Mandruzzato S, Callegaro A, Turcatel G, et al.: A gene
expression signature associated with survival in meta-
static melanoma. J Transl Med. 4:50, 2006
Panelli MC, Wang E, Phan G, et al.: Gene-expression
profiling of the response of peripheral blood mononuc-
lear cells and melanoma metastases to systemic IL-2
administration. Genome Biol 3, 2002
4. Useful Reviews
Marincola FM: The trouble with translational medicine.
J Intern Med. 2011 May
16. [Epub ahead of print]
K i r k w o o dJ M ,B u t t e r f i e l dL H ,T a r h i n iA A ,Z a r o u rH ,
Kalinski P, Ferrone S: Immunotherapy of Cancer in
2011 CA: A Cancer Journal for Clinicians [in press]
Ascierto ML, De Giorgi V, Liu Q et al.: An immunolo-
gic portrait of cancer. Journal of Translational Medicine,
(2011, in press).
G a j e w s k iT F ,F u e r t e sM ,S p a a p e nR ,e ta l . :M o l e c u l a r
profiling to identify relevant immune resistance mechan-
isms in the tumor microenvironment. Curr Opin Immu-
nol 23:286-92, 2011
Disis ML: Immunologic biomarkers as correlates of
clinical response to cancer immunotherapy. Cancer
Immunol Immunother. 60:433-42, 2011
Sznol M: Molecular markers of response to treatment
for melanoma Cancer J 17:127-33, 2011
Bedognetti D, Wang E, Sertoli MR, Marincola FM.
Gene-expression profiling in vaccine therapy and immu-
notherapy for cancer. Expert Rev Vaccines 6:555-65, 2010
Slota M, Lim JB, Dang Y, Disis ML: ELISpot for mea-
suring human immune responses to vaccines. Expert
Rev Vaccines 10:299-306, 2011
Gogas H, Eggermont AM, Hauschild et al: Biomarkers
in melanoma. Ann Oncol. 20 Suppl 6:vi8-13, 2009
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Page 6 of 20Simon R: Translational research in oncology: key bot-
tlenecks and new paradigms. Expert Rev Mol Med 12:
e32, 2010
Kirkwood JM, Tarhini AA, Panelli MC, Moschos SJ,
Zarour HM, Butterfield LH,
Gogas HJ: Next generation of immunotherapy for mel-
anoma. J Clin Oncol 26:3445-55, 2008
Freidlin B, McShane LM, Korn EL: Randomized clini-
cal trials with biomarkers:
design issues. J Natl Cancer Inst 3;102:152-60, 2011
5. Bioinformatics for Biomarkers Discovery
Zhao Y, Simon R: Development and validation of pre-
dictive indices for a continuous outcome using gene
expression profiles. Cancer Inform 9:105-114, 2010
Chaussabel D: Data management: it starts at the
bench. Nat Immunol. 10:1225-7, 2009
Chaussabel D, Quinn C, Shen J, et al.: A modular ana-
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7. Standardization and Harmonization of Sample
Collection and Use of Immunological Assays
A. Processing, Storage and Shipping of Blood Samples and
Serum for Immunological Studies - Technical Considerations
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Kierstead LS, Dubey S, Meyer B, et al.: Enhanced rates
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products/guidelines.html
Attig S, Price L, Janetzki S, Kalos M, Pride M, McNeil
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zation guidelines for HLA-peptide multimer assays
derived from results of a large scale international profi-
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Toward the harmonization of immune monitoring in
clinical trials: quo vadis? Cancer Immunol Immunother
57:285-288, 2008
Mander A, Gouttefangeas C, Ottensmeier C, et al.:
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Fahey JL, Aziz N, Spritzler J, et al.: Need for an exter-
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kines, and plasma markers of immune activation. Clin
Diagn Lab Immunol 7:540-548, 2000
Denny TN, Gelman R, Bergeron M, et al.: A North
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flow cytometric panLeukogating (PLG): a NIAID-DAIDS
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nents. Clin Vaccine Immunol 16:147-155, 2009
Smith SG, Joosten SA, Verscheure V, et al.: Identifica-
tion of major factors influencing ELISpot-based moni-
toring of cellular responses to antigens from
Mycobacterium tuberculosis. PLoS One 4:e7972, 2009
Hanekom WA, Dockrell HM, Ottenhoff TH, et al.:
Immunological outcomes of new tuberculosis vaccine
trials: WHO panel recommendations. PLoS Med 5:e145,
2008
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Comparison of cytokine ELISpot assay formats for the
detection of islet antigen autoreactive T cells. Report of
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D. Assays for Determination of Antitumor Immune-
Response in Clinical Trials
Examples
ELISPOT Q u a s tS ,Z h a n gW ,S h i v eC ,e ta l . :I L - 2
absorption affects IFN-gamma and IL-5, but not IL-4
producing memory T cells in double color cytokine ELI-
SPOT assays. Cell Immunol 237:28-36, 2005
Granzyme B ELISPOT Shafer-Weaver K, Rosenberg S,
Strobl S, et al.: Application of the granzyme B ELISPOT
assay for monitoring cancer vaccine trials. J Immunother
29:328-335, 2006
Modified ELISPOT Malyguine A, Strobl SL, Shafer-
Weaver KA, et al.: A modified human ELISPOT assay to
detect specific responses to primary tumor cell targets. J
Trans Med 2:9, 2004
FACS-based Cytotoxicity Assay Kim GG, Donnenberg
VS, Donnenberg AD, et al.: A novel multiparametric
flow cytometry-based cytotoxicity assay simultaneously
immunophenotypes effector cells: comparisons to a 4 h
51Cr-release assay. J Immunol Methods 325:51-66,
2007
D e v e v r eE ,R o m e r oP ,M a h n k eY D :L i v e C o u n tA s s a y :
concomitant measurement of cytolytic activity and phe-
notypic characterisation of CD8(+) T-cells by flow cyto-
metry. J Immunol Methods 311:31-46, 2006
Zaritskaya L, Shafer-Weaver KA, Gregory MK, et al.:
Application of a flow cytometric cytotoxicity assay for
monitoring cancer vaccine trials. J Immunother 32:186-
194, 2009
Maecker HT, Dunn HS, Suni MA, et al.: Use of over-
lapping peptide mixtures as antigens for cytokine flow
cytometry. J Immunol Methods 255:27-40, 2001
FACS/ELISPOT/TETRAMERS Whiteside TL, Zhao Y,
Tsukishiro T, Elder EM, Gooding W, Baar J: Enzyme-
linked immunospot, cytokine flow cytometry, and
tetramers in the detection of T-cell responses to a den-
dritic cell-based multipeptide vaccine in patients with
melanoma. Clin Cancer Res, 2003
8. Reporting Biomarkers Data in Publications
Examples
REMARK Recommendations
(accepted by most major journal included those pub-
lished by the American Society of Clinical Oncology and
the American Association for Cancer Research)
McShane LM, Altman DG, Sauerbrei W, et al.:
Reporting recommendations for tumor marker prognos-
tic studies (REMARK). J Natl Canc Inst 97:1180-1184,
2005
MIBBI Project - Guidelines Promotion
http://www.mibbi.org
Taylor CF, Field D, Sansone SA, et al.: Promoting
coherent minimum reporting guidelines for biological
and biomedical investigations: the MIBBI project. Nat
Biotechn 26:889-896, 2008
MIAME - Microarray Experiment
Brazma A, Hingamp P, Quackenbush J, et al.: Minimum
information about a microarray experiment (MIAME)-
toward standards for microarray data. Nat Genet
29:365-371, 2001
MIATA - T Cell Assays
http://www.miataproject.org
Janetzki S, Britten CM, Kalos M, et al.: “MIATA"-
minimal information about T cell assays. Immunity
31:527-528, 2009
Britten CM, Janetzki S, van der Burg SH, et al: Mini-
mal information about T cell assays: the process of
reaching the community of T cell immunologists in can-
cer and beyond. Cancer Immunol Immunother 60:15-22,
2011
MIFlowCyt - Flow Cytometry
Lee JA, Spidlen J, Boyce K, et al.: MIFlowCyt: the mini-
mum information about a Flow Cytometry Experiment.
Cytometry A 73:926-930, 2008
Data File for Flow Cytometry
Spidlen J, Moore W, Parks D, et al.: Data file standard
for flow cytometry, version FCS 3.1. Cytometry A 77:97-
100, 2010
Part II. High Throughput and New Technologies
for Biomarker Discovery: Arrays, Platforms, Tools
for The Bench and Online Resources
1. Genomic Biomarkers Discovery
A. Single Nucleotide Polymorphisms (SNPs) Arrays
Examples
Name: Affymetrix Genome-Wide Human SNP Array
6.0
Comment:1.8 million genetic markers, including more
than 906,600 single nucleotide polymorphisms (SNPs)
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Name: Affymetrix DMET Plus Premier Pack
Comment:Drug metabolism studies. Coverage of a
wide range of genetic variations, including common and
rare SNPs, insertions, deletions, tri-alleles, and copy




Name: Illumina Omni Microarray
Comment:Next generation genome-wide association
studies. The Omni family of microarrays will soon allow
researchers to assay up to 5 million markers per sample,
including comprehensive coverage of both common and
rare variants identified by 1000 Genomes Project. As
novel SNP sets are released into the public database,
researchers using Omni products will have exclusive





Name: Fluidigm Dynamic Array for SNP Genotyping
Comment:The Fluidigm Dynamic Arrays allow you to
use your existing TaqMan
® SNP Genotyping assays in a
flexible and cost effective fashion. Each dynamic array
allows you to setup up to 9,216 individual TaqMan




® Pre-Designed SNP Genotyping Assays
Comment:Includes over 4.5 million SNP assays,
including 3.5 million HapMap, and ~70,000 coding SNP
assays. This collection now includes ~160,000 validated





B. Comparative Genomic Hybridization (CGH) Arrays
Examples
Name:Agilent Human Genome CGH Microarrays
Comment: High-resolution tool for genome-wide
DNA copy number variation profiling. Comprehensive
probe coverage is enhanced with emphasis on known





Name: Nimblegen Cytogenetics (CGX) Arrays
Comment: Genome-wide analysis of DNA copy num-









Comment:Detection of germ line and heteroplasmic
mutations by delivering the complete mitochondrial
genome with minimal PCR in only 48 hours
Website:http://www.affymetrix.com/support/technical/
byproduct.affx?product=humitoreseq
2. Epigenomic Biomarkers Discovery
A. Methylation Arrays
Examples
Name: Agilent Human DNA Methylation Microarrays
Comment:The array is specifically designed for analysis
of methylated DNA derived from affinity-based isolation





Name: Nimblegen 2.1 M Whole-Genome Tiling Set
Comment:Whole-genome formats are available in two
versions: a 10-array set at 100 bp probe interval or a 4-
array set at > 200 bp probe interval
Website:http://www.nimblegen.com/products/methyla-
tion/whole_genome.html
Name: Illumina 450 K Infinium Methylation Bead-
Chip Kit
Comment:This assay allow to interrogate > 450,000




B. microRNA (miRNA) Arrays
Examples










Name: Exiqon’s miRCURY LNA microRNA Array
Comment:miRNA analysis
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analysis
C. Chromatin Immunoprecipitation (ChIP) Arrays (ChIP on
chip)
[ChIP-on-chip (chromatin immunoprecipitation-on-
chip), also known as Location Analysis (LA), is a high
throughput (genome-wide) identification and analysis of
DNA fragments that are bound by specific proteins such
as histones, transcriptional factors and polymerases]
Examples
















3. Transcriptomic Biomarkers Discovery
A. Expression Arrays
Examples
Name: Affymetrix Gene Chip Human Exon 1.0 ST
Array
Comment:Whole genome microarray. With approxi-
mately four probes per exon and roughly 40 probes per
gene, the GeneChip Human Exon 1.0 ST Array enables





Name: Agilent SurePrint G3 Human GE 8 × 60 K Kit
Comment:Whole genome microarray. The SurePrint G3
Human GE 8 × 60 K Microarrays and Human GE 4 × 44
K v2 Microarrays are based on updated transcriptome
databases for mRNA targets, while the SurePrint G3 arrays
also include probes for lincRNAs (long intergenic non-
coding RNAs). With the combination of mRNA and
lincRNAs, it is possible to perform two experiments on a




Name: Illumina HumanHT-12 v4 Expression Bead-
Chip Kits
Comment:The HumanHT-12 v4 Expression BeadChip
provides high throughput processing of 12 samples per
BeadChip. Each array on the HumanHT-12 v4 Expres-
sion BeadChip targets more than 31,000 annotated






® Plex 2.0 Reagent System (Lumi-
nex Assay)




Name: Procarta Transcription Factor Profiling Kits
(Luminex Assay)
Comment:Quantitate the DNA binding activity of up
to 44 different transcription factors (TFs) in a single




® Probe-Based Gene Expression
Analysis





Name: Fluidigm Dynamic Array for Single Cell Gene
Expression
Comment:The Fluidigm Dynamic Array enables you to
test up to 96 individual cells against 96 genes in a single
e x p e r i m e n t .T h ed y n a m i ca r r a ya s s e m b l e st h ec D N A




Name: Nanostring nCounter Analysis System for digital
gene expression analysis
Comment: The nCounter Analysis System utilizes a
novel digital technology that is based on direct multi-
plexed measurement of gene expression and offers high
levels of precision and sensitivity (< 1 copy per cell).
The technology uses molecular “barcodes” and single
molecule imaging to detect and count hundreds of
unique transcripts in a single reaction.
Website: http://www.nanostring.com/applications/
technology/
4. Proteomic Biomarkers Discovery
A. Protein and Phosphoprotein Assays
Examples
Name: Nodality
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advanced multiparametric quantitative flow cytometry to
measure compound effects on multiple signaling cas-
cades in a cell-type-specific manner
Website:http://www.nodalityinc.com/
Name: NanoPro Immunoassay
Comment:Characterization of proteins in extremely
small and precious samples. Unlike traditional protein
analysis techniques which require thousands to millions
of cells, these assays require as few as 25 cells per assay
Website:http://www.cellbiosciences.com/nanopro.html
Name: Invitrogen Immunoassays
Comment:Wide range of immunoassays using antibody
pairs for single-analyte (ELISA kits) as well as multi-
analyte (Lumibex assays) analysis or accurate quantita-




Name: Procarta Cytokine Profiling Assays (Luminex
Assay)
Comment:Quantitatively measure 3-30 cytokine pro-
teins simultaneously from a variety of matrices including
cell culture supernatants, serum or plasma
Website:http://www.panomics.com/index.php?
id=products_luminexAssays
Name: SearchLight Multiplex Immunoassay Kits
Comment:As many as 16 proteins (4 × 4 array in each
well) can be measured per well simultaneously with
each 50 μl sample
Website:http://www.aushon.com/Products-and-Ser-
vices.php
Name: MSD Multiplex Cytokines and Chemokines
Comment:96-well; multiplex cytokine/chemokine kits
for up to ten (10) analytes per well.
384-well: Order multiplex cytokine/chemokine kits for
up to four (4) analytes per well
Website:http://www.mesoscale.com
Name: Zeptomark
Comment:Protein profiling for analysis of cell signaling
pathways
Website:http://www.zeptosens.com/en/
Name: Signaling Protein Luminex Assays
Comment:Multiplex assays for measuring signal trans-
duction, post-translational modification & cleaved pro-






Name: VeraCode Carboxyl Bead Sets and BeadXpress
Reader
Comment:Multiplexed protein arrays (up to 48 immu-
noassays in a single reaction in a standard 96-well
microplate: detection of protein as low as 10 pg/ml)
Website:http://www.illumina.com/products/veracode_-
carboxyl_bead_sets.ilmn
Name: Procarta SH2 Domain Plex Profiling Kits
(Luminex Assay)
Comment:Profile phosphotyrosine protein interactions
against 30 SH2 binding in a single well using treated




Comment:Advanced, high-content, functional protein
microarray enables to scan thousands of proteins (>
9000) in as little as one day. Highly sensitive results for
protein-protein interaction, kinase substrate identifica-
tion, and serum profiling studies
Website:http://www.invitrogen.com/protoarray
Name: Metal Nanoparticle Probes and Dynamic Light
Scattering
Comment:This assay is based on the use of gold nano-
particle probes combined with dynamic light scattering
(DLS) technique, named nanoDLSAY, a highly sensitive,
fast and convenient one-step homogeneous immunoas-




B. Multicolor Cytometric Systems
Examples
Name: BD LSRFortessa™ Cell Analyzer






Comment: Three lasers, up to 8 colors, compact bench-
top flow cytometer that is small in size; MACSQuant
®
Analyzer allows researchers to perform sensitive rare
cell analysis using magnetic separation
Website:http://www.miltenyibiotec.com/downloads/
6760/6764/18602/MQ_brochure.pdf
Name: CyAn ADP Analyzer
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system
Website:http://www.accuricytometers.com/products/
5. Next Generation Sequencing: Whole Genomic and
Transcriptomic Sequencing Systems
Next generation sequencing, possible applications:
W h o l eG e n o m ea n dT r a n s c r i ptome Sequencing-Based
analysis, Gene Regulation Analysis, SNP Discovery and
Structural Variation Analysis, Cytogenetic Analysis,
DNA-Protein Interaction Analysis (ChIP-Seq), Sequen-
cing-Based Methylation Analysis, Small RNA Discovery
and Analysis
Examples
Name: Illumina - several systems, examples: HiSeq




Name: Roche - several systems, examples: Genome




Name: Applied Biosystems - several systems, examples:





Name: Ion Torrent PGM
Comment:Next generation sequencing: semiconductor
technology allows runs in about 2 hours.
Website:http://www.iontorrent.com/products-ion-pgm/
Name:PacBio RS
Comment:Third generation sequencing: Long read-
lengths, single molecule sequencing
Website:http://www.pacificbiosciences.com/products
6. Software and Tools for Data Analysis
A. Microarrays/Sequencing Data Analysis
Examples:
Name: BRB - ArrayTools
Comment:Microarray/array CGH analysis. BRB-Array
Tools was developed by Dr. Richard Simon and BRB-
ArrayTools Development T e a m ,N C I ,N I H .T h ep r o -





Comment:Next generation sequencing technologies,
including gene expression and DGE, RNA-seq and
alternative splicing, copy number and association, ChIP-
chip, ChIP-seq, microRNA and SNP association study
Website:http://www.partek.com/
License needed:Yes
Name: Nexus Copy Number








Name: mAdb (aka Mad Bee)




Comment:Tools for the analysis and comprehension of





Comment:MATLAB is a high-level technical comput-
ing language and interactive environment for algorithm

















Comment:Gene expression analysis software package
that includes visualization tools to help analyze microarray
data, including Venn diagrams, a scatter plot, heat maps





Comment:Statistical tools for fast visualization and
analysis of expression and genomic structural variation
data
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Comment:User-friendly web-based tool for the proces-









Name: SAM: Significance Analysis of Microarrays








B. Next Generation Sequencing Data Analysis
Blog
Name: SEQanswers
Comment:SEQanswers is a blog founded to be an
information resource and user-driven community
focused on all aspects of next-generation genomics. A
reasonably thorough table of next-gen-seq software







Comment:Cufflinks assembles transcripts, estimates
their abundances, and tests for differential expression
and regulation in RNA-Seq samples. It accepts aligned
RNA-Seq reads and assembles the alignments into a




Comment:Bowtie is an ultrafast, memory-efficient
short read aligner. It aligns short DNA sequences
(reads) to the human genome at a rate of over 25 mil-
lion 35-bp reads per hour. Bowtie indexes the genome
with a Burrows-Wheeler index to keep its memory foot-
print small: typically about 2.2 GB for the human gen-




Comment:TopHat is a program that aligns RNA-Seq
reads to a genome in order to identify exon-exon splice
junctions. It is built on the ultrafast short read mapping




Comment:O a s e si sade novo transcriptome assembler
designed to produce transcripts from short read sequen-
cing technologies, such as Illumina, SOLiD, or 454 in
the absence of any genomic assembly
Website:http://www.ebi.ac.uk/~zerbino/oases/
License needed:No
Name: Genomatix Genome Analyzer (GGA) and Geno-
matix Software Suite (GSS)
Comment:GGA comprehensive second-level analysis of
Next Generation Sequencing (NGS) data from ChIP-
Seq, RNA-Seq or genotyping experiments. GSS conducts
a scientific analysis of genomic data in gene regulation,





Comment:genome assembly algorithms recommended





C. Multicolor Cytometric Data-Analysis
Examples
Name: FlowJo
Comment:FlowJo is designed around the structure of
flow data and the researcher’s experiments. Through
FlowJo’s patent-pending Groups structure, for example,




Comment:Load FCS files from instruments and do
FACS data analysis with a full set of region tools and
gates. The algorithms allow for rapid generation of reg-
isters with frequencies/numbers of all possible supheno-
type combinations. Can be used to input data for cluster
analysis and heat maps, allowing rapid visualization of
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gram that produces presentation quality graphics and




Comment:FCS Express is designed to bring the power
sophisticated analysis protocols to users in an intuitive,




Comment:GemStone is software for analysis of high-
dimensional, flow cytometry data. Based on patented
Probability State Modeling technology, GemStone elimi-
nates some problems that have faced flow cytometry.
Subjective gating and associated errors are eliminated.
Population overlaps in multidimensional data are





Comment:SPICE is a data mining software application
that analyzes large FLOWJO data sets from polychro-
matic flow cytometry and organizes the normalized data
graphically. SPICE enables users to discover potential




7. Software and Tools for Function and Pathway Analysis
Examples
Name: Ingenuity Pathway Analysis (IPA)
Comment:User friendly software that allows analysis of




Comment:User friendly software that allows analysis of
biological and chemical systems
Website:http://www.genego.com/about.php
License needed:Yes
Name: Ariadne Pathway Studio
Comment:Analysis of biological system with an inter-
active software interface and the computational










Comment:Collection of manually drawn pathway maps
representing knowledge on the molecular interaction




Comment:BioCarta pathway provides displays of gene
interactions within pathways for human cellular pro-




Name: Interactive Genomics Viewer
Comment:The Integrative Genomics Viewer (IGV) is a
high-performance visualization tool for interactive
exploration of large, integrated datasets. It supports a
wide variety of data types including sequence align-




Comment:Gene Set Enrichment Analysis (GSEA) is a
computational method that determines whether an a
priori defined set of genes shows statistically significant,





Comment:A tool for biological interpretation of ‘omic’
data - including data from gene expression microarrays.
Omic experiments often generate lists of dozens or hun-




Comment:Set of tools that enables the user to translate
between disparate ids for the same gene. It uses data
from the UCSC, LocusLink, Unigene, OMIM, Affyme-
trix and Jackson data sources to determine how different
ids relate. Supported id types include, gene symbols and
names, IMAGE and FISH clones, GenBank accession




Name: PANTHER Classification System
Comment:Panther is a resource that classifies genes by
their functions, using published scientific experimental
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tion even in the absence of direct experimental evidence.






















Name: Gene Expression Omnibus (GEO)
Comment:Public functional genomics data repository
supporting MIAME-compliant (Minimum information
about a microarray experiment) data submissions.
Array- and sequence-based data are accepted. Tools are
provided to help users query and download experiments
and curated gene expression profiles
Website:http://www.ncbi.nlm.nih.gov/geo/
Name: Catalogue Of Somatic Mutations In Cancer
(COSMIC)
Comment:COSMIC is designed to store and display
somatic mutation information and related details and
contains information related to human cancers
Website:http://www.sanger.ac.uk/genetics/CGP/
cosmic/
Name: The Cancer Genome Atlas (TCGA)
Comment:The Cancer Genome Atlas (TCGA) Data
Portal provides a platform for researchers to search,
download, and analyze data sets generated by TCGA.
Launched in 2006 as a partnership between the National
Cancer Institute and the National Human Genome
Research Institute, both NIH components, The Cancer
Genome Atlas (TCGA) has developed a comprehensive
strategy for comparing the genome of cancer cells to the
genome of normal cells from the same patient
Website:http://cancergenome.nih.gov/
Name: The Human Protein Atlas
Comment:The Human Protein Atlas portal is a pub-
licly available database with millions of high-resolution
images showing the spatial distribution of proteins in 46
different normal human tissues and 20 different cancer
types, as well as 47 different human cell lines. The data
is released together with application-specific validation
performed for each antibody. The database was devel-
oped in a gene-centric manner with the inclusion of all
human genes predicted from genome efforts
Website:http://www.proteinatlas.org
Name:DIP (Database of Interacting Proteins)
Comment:The DIP database catalogs experimentally
determined interactions between proteins. It combines
information from a variety of sources to create a single,
consistent set of protein-protein interactions
Website:http://dip.doe-mbi.ucla.edu/dip/Main.cgi
Name:MINT (Molecular INTeraction Database)
Comment:MINT focuses on experimentally verified
protein-protein interactions mined from the scientific
literature by expert curators. The curated data can be
analyzed in the context of the high throughput data and
viewed graphically with the ‘MINT Viewer’
Website:http://mint.bio.uniroma2.it/mint/Welcome.do
Name: Human Protein Reference Database
Comment:The Human Protein Reference Database
represents a centralized platform to visually depict and
integrate information pertaining to domain architecture,
post-translational modifications, interaction networks
and disease association for each protein in the human
proteome
Website:http://www.hprd.org
Name: Cancer Genome Anatomy Project (CGAP)
Comment:The NCI’s Cancer Genome Anatomy Project
sought to determine the gene expression profiles of nor-
mal, precancer, and cancer cells, leading eventually to
improved detection, diagnosis, and treatment for the
patient. Resources generated by the CGAP initiative are
available to the broad cancer community
Website:http://cgap.nci.nih.gov/cgap.html
Name: caBIG
Comment:caBIG stands for the cancer Biomedical
Informatics Grid. caBIG is an information network
enabling members of the cancer community - research-








Comment:deepBase is a database for annotating and
discovering small and long ncRNAs (microRNAs,
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sequencing data
Website:http://deepbase.sysu.edu.cn/miRDeep.php
Name: Gene Ontology Annotation (UniProtKB-GOA)
Database
Comment:The UniProtKB-GOA project aims to pro-
vide high-quality Gene Ontology (GO) annotations to
proteins in the UniProt Knowledgebase (UniProtKB)
and International Protein Index (IPI) and is a central




Comment:The ProtFun 2.2 server produces ab initio
predictions of protein function from sequence
Website:http://www.cbs.dtu.dk/services/ProtFun/
Name: TRANSFAC 7.0 Public 2005
Comment:Data on transcription factors, their experi-
mentally-proven binding sites, and regulated genes. Its
broad compilation of binding sites allows the derivation




Comment:OptiTope aims at assisting immunologists in
designing epitope-based vaccines. It is an easy-to-use
tool to determine a provably optimal set of epitopes
with respect to overall immunogenicity in a specific
individual or a target population, free of charge
Website:http://www.epitoolkit.org/optitope
Name: Cancer Central Clinical Database (C3D)
Comment:Cancer Central Clinical Database (C3D) is a
clinical trials data management system. C3D collects
clinical trial data using standard case report forms
(CRFs) based on common data elements (CDEs)
Website:https://cabig.nci.nih.gov/tools/c3d
Name: UCSC Genome Browser
Comment:Provides a large database of publicly avail-
able sequence and annotation data along with an inte-
grated tool set for examining and comparing the
genomes of organisms, aligning sequence to genomes,
and displaying and sharing users’ own annotation data
Website:http://genome.ucsc.edu/
Name: Next Bio
Comment:Exhaustive collection of public microarray
data. NextBio’s platform combines powerful tools with
unique correlated content. With NextBio you can search
tens of thousands of studies containing billions of data
points spanning different experimental platforms, organ-
isms and data types
Website:http://www.nextbio.com/b/corp/faq.nb
Name: SYFPEITHI
Comment:SYFPEITHI is a database comprising more
than 7,000 peptide sequences known to bind class I and
class II MHC molecules. The entries are compiled from
published reports only
Website:http://www.syfpeithi.de/
Name: Melanoma Molecular Map Project
Comment:MMMP Databases, putting together the
pieces of the melanoma puzzle. Seven interconnected
databanks for the interactive collection, update and con-
sultation of the translational and clinical information on
melanoma biology and treatment.
Website:http://www.mmmp.org
Name: The Targeted Therapy Database (TTD)
Comment:Systematic collection of the scientific knowl-
edge regarding the development of targeted therapy for
melanoma
Website:http://www.mmmp.org
10. Tools for the Bench and Other Useful Websites
A. Primer Design Software
Examples
Name: Primer3
Comment:Primer3 is a free online tool to design and
analyze primers for PCR and real time PCR experi-
ments. Primer3 can also select single primers for
sequencing reactions and can design oligonucelotide
hybridization probes
Website:http://frodo.wi.mit.edu/primer3
Name: Oligo Analyzer 3.0
Comment:Software developed by IDT (Integrated
DNA Technologies) that analyzes physical properties of
a specific oligo sequence. The results show a comple-
mentary sequence, oligo length, GC content, melting





Comment:MethPrimer is a program for designing
bisulfite-conversion-based methylation PCR Primers. It
can design primers for Methylation-Specific PCR (MSP),




B. Transcription Factors Binding Sites Prediction Software
Examples
Name: TFSEARCH
Comment:TFSEARCH predicts transcription factors
binding sites from a given sequence. It does simple cor-
relation calculation with binding site profile matrices
Website:http://www.cbrc.jp/research/db/TFSEARCH.
html
C. Design of Antisense Oligonucleotides, Nucleic Acid
Probes, siRNA Software
Name: Sfold
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for rational siRNA design. It supports target accessibility
prediction and rational design of antisense oligonucleo-
tides (ASO) and nucleic acid probes. It can design an










Comment:A resource for predicted microRNA targets









Comment:This software first finds putative microRNA








Comment:miRanda is an algorithm for finding geno-
mic targets for microRNAs
Website:http://www.microrna.org/microrna/home.do
E. Alternative Splicing Analysis
Example
Name: SpliceCenter
Comment:The SpliceCenter applications are user-
friendly tools that provide information on the target
location of probesets, primers, or siRNAs within the




F. Linkage Disequilibrium Analysis
Examples
Name: PhAT
Comment:It analyzes SNP data, showing pairwise
Linkage Disequilibrium of various types (r
2,r ,D ’ and
abs(D)) and producing graphical matrices of obtained
results
Website:http://pharmgat.org/Tools/pbtoldplotform




Comment: Computer Model. Development of compu-
ter models that aim to predict the response to biological
therapies in cancer patients
Website:http://www.immuneering.com/
Name: Cellumen CellCiphr Patient Sample Profiling
Comment:To use the cellular systems biology
approach to improve patient stratification for clinical
trial enrollments. Cellumen is collaborating with the
Mayo Clinic and Foundation to create panels of cellular
biomarkers using multiplexed fluorescence to apply to




Comment: Lab Management. Biotracker is a specialty
Lab Information Management Solution (LIMS) for
enhancing productivity and effectiveness in life sciences
research laboratories
Website:http://www.ocimumbio.com/lims2/products/
Name: Gene’s Logic Expression Array Analysis
Comment:Array analysis support; team dedicated to
statistical and bioinformatic analyses of microarray data,




Name: Microsoft Word Add-In for the GenePattern
Reproducible Research Document (GRRD)
Comment:To facilitate publishing reproducible results,
GenePattern automatically captures the history of any
computational work being done, allowing scientists to






Comment:Archive of biology data and software, estab-
lished in 1989 to promote public access to freely avail-




Comment:Tools for searching antibodies, siRNA/
shRNA, ELISA, cDNA clones, proteins/peptides, micro-
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Comment:The Inno.CNT website gives an updated and
wide overview of the research status of carbon nano-
tubes as one of the most promising nanomaterial to




Comment:The ObservatoryNano provides wide-ran-




Comment:Nanofutures is an integration platform
aimed at becoming a long-lasting nanotechnology hub,




Comment:Nanotechnology Medicine brings you infor-
mative nanomedicine articles, educational nanomedicine
videos, and lively nanomedicine dialogue and chatter.
Website: http://nanotechnologymedicine.org/
I. Clinical Trials Registries
Example
Name: Clinical Trial Registries
Comment:The five clinical trials registries approved by






Immune biomarkers are playing an increasingly impor-
tant role in the successful development, clinical evalua-
tion, and immune monitoring of cancer
immunotherapies. The references, products and online
resources in this Cancer Immunotherapy Biomarkers
Resource Document were identified by the authors and
the SITC/iSBTc Taskforce on Immunotherapy Biomar-
kers to support the discovery, evaluation and application
of biomarkers for cancer immunotherapy. These
selected references and links serve as a compass to
point investigators to useful resources in this ever grow-
ing, and important field of cancer immunotherapy bio-
markers. Emerging issues surrounding cancer
immunotherapy biomarker discovery and clinical appli-
cation will continue to be addressed in upcoming SITC
Annual Meetings and Associated Programs [13].
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